Abstract
Studies have demonstrated that all 3 of the FDA-approved COVID-19 vaccines (Pfizer-BioNTech, Moderna, and Johnson & Johnson) are effective at reducing SARS-CoV-2-related hospitalizations, severe disease, and death. While these vaccinations have demonstrated a compelling safety profile, no discussion regarding the impact of COVID-19 vaccination on the exacerbation of slow-flow vascular malformations (SFVMs) has been had. We present the first case series of 3 consecutive patients who demonstrated clinical emergence or exacerbation of venous malformation status-post COVID-19 vaccination. As trauma, infection, and systemic inflammation can contribute to exacerbation of these vascular anomalies, COVID-19 vaccination may contribute to the clinical emergence and exacerbation of vascular malformations in patients with initial subclinical presentation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
